Type I IFN-activated lung monocytes and macrophages as initiators and drivers of fibrosis at the alveolar barrier in IPF

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease with limited therapeutic options. Although macrophages have been implicated in pathogenesis in murine models, their role in human disease remains unclear. Here, we present a comprehensive, unbiased single-cell transcriptomic and regulon atlas of myeloid cells from the alveolar barrier and lung tissue. We demonstrate that alveolar barrier macrophages are transcriptionally distinct from their lung tissue counterparts, exhibiting a striking upregulation of type I interferon (IFN) signalling in IPF. Circulating monocytes from IPF patients are primed for type I IFN responses, particularly in early disease, and monocytes are enriched with type I IFN-associated genes at lung sites of early fibrosis. These findings suggest a central role for type I IFN-activated monocytes in the initiation of fibrosis, and for alveolar barrier-related, type I IFN-activated macrophages in perpetuating fibrosis. These insights provide a rationale for therapeutically targeting monocytes in early stages of IPF.

Article activity feed